HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Fujioka, Y. Articles by Fong, L. G. Search for Related Content PubMed PubMed Citation Articles by Fujioka, Y. Articles by Fong, L. G. Social Bookmarking                      What's this?

The Journal of Lipid Research, Vol. 39, 2339-2349, December 1998
Copyright © 1998 by Lipid Research, Inc.

Original Article

Multiple processes are involved in the uptake of chylomicron remnants by mouse peritoneal macrophages

Correspondence to: Loren G. Fong.

The processes responsible for the uptake of chylomicron remnants by macrophages were investigated using freshly isolated cells from low density lipoprotein (LDL) receptor, very low density lipoprotein (VLDL) receptor and apolipoprotein E knockout mice. In peritoneal macrophages from normal mice, the metabolism of chylomicron remnants was inhibited 40% by anti-LDL receptor antibody and 60% by a high concentration of receptor-associated protein (RAP). Together they reduced the amount processed by 70%. Digestion of cell proteoglycans decreased remnant degradation by 20% while the addition of acetyl-LDL had no effect. When LDL receptors were absent, the absolute rates of metabolism were less than that of normal cells and were not inhibited by the anti-LDL receptor antibody; the rates, however, were reduced to less than half by RAP. These suggest that the LDL receptor-related protein (LRP) or another LDL receptor family member(s) contributes to chylomicron remnant uptake and becomes the major mechanism of uptake when LDL receptors are absent. In contrast, the VLDL receptor was not involved as its absence did not affect chylomicron remnant metabolism. Similarly, the absence of apoE production did not affect the amount of remnant uptake; however, the proportion that was sensitive to RAP was eliminated. The level of LRP expression was not altered in these cells whereas there was a decrease in LDL receptors. This suggests that the apoE content of chylomicron remnants is sufficient for its recognition by LDL receptors but additional apoE is required for its uptake by the LRP and that there is an up-regulation of a non-LDL receptor family mechanism in apoE deficiency.

Together these studies suggest that even in the absence of LDL receptors or apoE secretion, chylomicron remnants could contribute to lipid accumulation in the artery wall during atherogenesis.—Fujioka, Y., A. D. Cooper, and L. G. Fong. Multiple processes are involved in the uptake of chylomicron remnants by mouse peritoneal macrophages. J. Lipid Res. 1998. 39: 2339–2349.

Supplementary key words: apoE, VLDL receptor, LDL receptor, knockout mice, THP-1 cells, LRP, RAP, scavenger receptor

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				L. Hu, L.S.M. Boesten, P. May, J. Herz, N. Bovenschen, M.V. Huisman, J.F.P. Berbee, L.M. Havekes, B.J.M. van Vlijmen, and J.T. Tamsma Macrophage Low-Density Lipoprotein Receptor-Related Protein Deficiency Enhances Atherosclerosis in ApoE/LDLR Double Knockout Mice Arterioscler. Thromb. Vasc. Biol., December 1, 2006; 26(12): 2710 - 2715. [Abstract] [Full Text] [PDF]

				V. Llorente-Cortes and L. Badimon LDL Receptor-Related Protein and the Vascular Wall: Implications for Atherothrombosis Arterioscler. Thromb. Vasc. Biol., March 1, 2005; 25(3): 497 - 504. [Abstract] [Full Text] [PDF]

				A. Kawakami, M. Tani, T. Chiba, K. Yui, S. Shinozaki, K. Nakajima, A. Tanaka, K. Shimokado, and M. Yoshida Pitavastatin Inhibits Remnant Lipoprotein-Induced Macrophage Foam Cell Formation Through ApoB48 Receptor-Dependent Mechanism Arterioscler. Thromb. Vasc. Biol., February 1, 2005; 25(2): 424 - 429. [Abstract] [Full Text] [PDF]

				S.-J. Lee, S. Kadambi, K. C-W. Yu, C. David, S. Azhar, A. D. Cooper, and S. Y. Choi Removal of chylomicron remnants in transgenic mice overexpressing normal and membrane-anchored hepatic lipase J. Lipid Res., January 1, 2005; 46(1): 27 - 35. [Abstract] [Full Text] [PDF]

				S.-J. Lee, I. Grosskopf, S. Y. Choi, and A. D. Cooper Chylomicron remnant uptake in the livers of mice expressing human apolipoproteins E3, E2 (Arg158->Cys), and E3-Leiden J. Lipid Res., December 1, 2004; 45(12): 2199 - 2210. [Abstract] [Full Text] [PDF]

				V. Llorente-Cortes, M. Otero-Vinas, S. Sanchez, C. Rodriguez, and L. Badimon Low-Density Lipoprotein Upregulates Low-Density Lipoprotein Receptor-Related Protein Expression in Vascular Smooth Muscle Cells: Possible Involvement of Sterol Regulatory Element Binding Protein-2-Dependent Mechanism Circulation, December 10, 2002; 106(24): 3104 - 3110. [Abstract] [Full Text] [PDF]

				V. Llorente-Cortes, M. Otero-Vinas, E. Hurt-Camejo, J. Martinez-Gonzalez, and L. Badimon Human Coronary Smooth Muscle Cells Internalize Versican-Modified LDL Through LDL Receptor-Related Protein and LDL Receptors Arterioscler. Thromb. Vasc. Biol., March 1, 2002; 22(3): 387 - 393. [Abstract] [Full Text] [PDF]

				S. Kosaka, S. Takahashi, K. Masamura, H. Kanehara, J. Sakai, G. Tohda, E. Okada, K. Oida, T. Iwasaki, H. Hattori, et al. Evidence of Macrophage Foam Cell Formation by Very Low-Density Lipoprotein Receptor : Interferon-{{gamma}} Inhibition of Very Low-Density Lipoprotein Receptor Expression and Foam Cell Formation in Macrophages Circulation, February 27, 2001; 103(8): 1142 - 1147. [Abstract] [Full Text] [PDF]

				F. B. Kraemer and J. Suzuki Lipoprotein Receptors, Macrophages, and Sphingomyelinase Arterioscler. Thromb. Vasc. Biol., December 1, 2000; 20(12): 2509 - 2510. [Full Text] [PDF]

				K. C-W. Yu, Y. Jiang, W. Chen, and A. D. Cooper Rapid initial removal of chylomicron remnants by the mouse liver does not require hepatically localized apolipoprotein E J. Lipid Res., November 1, 2000; 41(11): 1715 - 1727. [Abstract] [Full Text]

				R. W. Mahley, Y. Huang, and S. C. Rall , Jr. Pathogenesis of type III hyperlipoproteinemia (dysbetalipoproteinemia): questions, quandaries, and paradoxes J. Lipid Res., November 1, 1999; 40(11): 1933 - 1949. [Abstract] [Full Text]